Regardless, we would recommend the use of SGLT2 inhibitors in CRT patients for both HF optimisation and anti-arrhythmic purposes, which may well prove to beneficially impact BVP% and reduce the risk of appropriate and inappropriate shocks in those with CRT-D. Here, SLC5A2 is linked to hydrops fetalis.